中国实用内科杂志2025，Vol.45Issue(1)：67-72,6.DOI:10.19538/j.nk2025010110
基因突变结合临床合并症指数对骨髓增生异常综合征预后的影响研究
Effect of gene mutation combined with clinical complication index on prognosis of myelodysplastic syndrome
摘要
Abstract
Objective To investigate the impact of gene mutation and age-adjusted Chilson Comorbidity Index(aCCI)on the prognosis of patients with myelodysplastic syndrome(MDS).Methods Data of 155 patients with myelodysplastic syndrome(MDS)who underwent treatment in the First Affiliated Hospital of Zhejiang Chinese Medical University and other partner hospitals from March 2019 to October 2023 were selected.Cox proportional regression risk models were utilized to screen the risk factors influencing the prognosis of MDS patients.Results The IPSS-R risk stratification(HR 1.337,95％CI 1.055-1.694),aCCI(HR 1.317,95％CI 1.164-1.490),mutation genes TP53(HR 3.532,95％CI 2.034-6.135),NRAS(HR 3.278,95％CI 1.528-7.031)and ZRSR2(HR 4.163,95％CI 1.625-10.665)all exerted negative impacts on the overall survival(OS)of MDS patients(P＜0.05).Meanwhile,aCCI(HR 1.393,95％CI 1.114-1.743),the mutated gene RUNX1(HR 2.259,95％CI 1.043-4.890)and KRAS(HR 4.398,95％CI 1.471-13.148)adversely affected the leukemia-free survival(LFS)in MDS patients(P＜0.05).Conclusion Gene mutation and aCCI influence the prognosis of MDS patients,and there might be a recessive connection between these two risk factors.关键词
骨髓增生异常综合征/基因突变/查尔森合并症指数/年龄/预后Key words
myelodysplastic syndrome/gene mutation/charlson comorbidity index/age/prognosis分类
医药卫生引用本文复制引用
周铭,林圣云,胡蒙蒙,沈英英,郑智茵,武利强,俞庆宏,王博,叶宝东,沈建平..基因突变结合临床合并症指数对骨髓增生异常综合征预后的影响研究[J].中国实用内科杂志,2025,45(1):67-72,6.基金项目
浙江省科技厅重点研发项目(2019C03047) （2019C03047）
